CCA
HZNP

Catalyst Capital Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Catalyst Capital Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-94
Closed -$10K – 434
2021
Q3 		$10K Buy
+94
New +$9.76K ﹤0.01% 391

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Catalyst Capital Advisors's HZNP Position: Q4 2021 in Review

Catalyst Capital Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2021, closing a stake of 94 shares — an estimated $10K sold.

Catalyst Capital Advisors first reported a position in HZNP in Q3 2021 and held it in 1 quarter. The position peaked at $10K in Q3 2021. 611 funds tracked by Wall St. Rank hold HZNP as of Q4 2021.

  • Catalyst Capital Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2021 after selling out during the quarter.
  • Catalyst Capital Advisors sold 94 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2021, an estimated $10K.
  • Catalyst Capital Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 1 quarter.
  • Catalyst Capital Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $10K in Q3 2021.
  • 611 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2021.

Based on Catalyst Capital Advisors's 13F filing for Q4 2021, filed 10 Feb 2022.